What this is
- The article proposes a shift from traditional antiaging aesthetics to a pro-aging framework in aesthetic medicine.
- This framework emphasizes preserving tissue function and resilience rather than merely correcting visible aging signs.
- It integrates insights from and suggests that aesthetic interventions can modulate biological aging processes.
Essence
- redefines aesthetic medicine by focusing on tissue resilience and function over mere correction of aging signs. It proposes that aesthetic practices can align with biological aging processes, although empirical support remains limited.
Key takeaways
- The skin serves as an ideal model for studying aging due to its visible and functional aging signs, such as dermal thinning and impaired barrier function.
- The pro-aging framework shifts the focus of aesthetic interventions from reactive corrections to proactive strategies that preserve tissue health and resilience.
- Current aesthetic practices can incorporate biostimulatory injectables and combination therapies to enhance tissue quality, though many concepts remain largely theoretical and require further validation.
Caveats
- The framework is primarily conceptual and lacks direct clinical evidence supporting its biological impact. Most existing studies are short-term and do not assess long-term effects on tissue biology.
- There is no consensus on reliable biomarkers of biological age that reflect the efficacy of aesthetic interventions, limiting the practical application of the pro-aging framework.
Definitions
- Longevity aesthetics: A framework in aesthetic medicine focusing on preserving tissue function and resilience rather than merely correcting visible aging signs.
- Geroscience: The study of the biological processes of aging and how they can be modified to improve health span.
Simplified
THE SKIN: AN ACCESSIBLE MODEL ORGAN FOR AGING AND INTERVENTION
The integumentary system provides a unique and practical interface for studying aging biology. The skin visibly and functionally manifests the classic hallmarks of aging, including genomic instability, epigenetic alterations, mitochondrial dysfunction, cellular senescence, and altered intercellular communication.3,4 Clinically, this translates to clinical signs well-known in aesthetic practice: dermal thinning, reduced elasticity, impaired barrier function, and delayed wound healing.5
Critically, these processes are not confined to the epidermis and dermis. The subcutaneous adipose layer, connective tissue, and microvascular networks, all critical to surgical and energy-based outcomes, undergo analogous age-related decline.6 For instance, adipose-derived stem cell exhaustion and senescent cell accumulation in subcutaneous tissue can impair volume retention and healing capacity.7 The skin's accessibility for noninvasive imaging (eg, reflectance confocal microscopy and optical coherence tomography) and repeated sampling (eg, transepidermal water loss, sebum secretion, and tape stripping for biomarkers) makes it an ideal organ for longitudinal study.8 This positions aesthetic practice, which routinely interfaces with this tissue, as a potential frontier for translational human aging research, provided claims are carefully validated.
FROM ANTIAGING TO PRO-AGING: A PARADIGM SHIFT
The traditional antiaging model is inherently reactive and structural. Interventions, such as filler injection or facelift surgery, are employed to replace lost volume or resect loose skin, offering excellent correction but often after aging changes are established.9 This approach may not address the underlying biological “milieu” that led to the changes and could, in some cases of repetitive trauma or inflammation, inadvertently exacerbate tissue fragility. Table 1 provides a conceptual comparison of the 2 frameworks.
The pro-aging framework, informed by geroscience, proposes a complementary strategy. Its primary objective shifts toward preserving tissue function and resilience, conceptualizing aging as a modifiable process rather than an inevitable enemy.10 The timing of interventions would theoretically consider biomarkers of tissue health, potentially guiding earlier, preventative strategies.11,12 The role of procedures expands from structural correction to include biological modulation, such as laser therapy to reduce oxidative stress or platelet-rich plasma to support regenerative signaling.13,14
| Dimension | Traditional antiaging paradigm | Pro-aging/longevity aesthetics framework |
|---|---|---|
| Primary objective | Correction or concealment of visible age-related changes | Preservation of tissue function, resilience, and biological integrity |
| Concept of aging | Undesirable process to be reversed or minimized | Regulated biological processes that can be modulated |
| Timing of intervention | Reactive, initiated after phenotypic aging appears | Preventive, potentially earlier, guided by tissue condition and risk profiles |
| Primary outcome measures | Visual improvement, patient satisfaction, short-term safety | Functional tissue quality, durability of outcomes, biological markers (hypothesis driven) |
| Biological focus | Limited consideration of underlying aging mechanisms | Informed by hallmarks of aging (eg, inflammaging, senescence) |
| Role of procedures | Structural correction or surface modification | Biological modulation and tissue support (theoretical) |
| Evidence base | Established for aesthetic outcomes | Largely conceptual; requires longitudinal validation |
| Clinical limitations | May not address upstream aging drivers | Risk of overinterpretation without robust biomarkers |
| Ethical considerations | Focus on aesthetic benefit | Emphasis on evidence-based restraint and transparency |
PATHWAYS INTERSECTIONS: AESTHETIC MODALITIES AND AGING HALLMARKS
The scientific plausibility of longevity aesthetics rests on evidence that common aesthetic interventions interact with fundamental aging pathways.3,15,16
CLINICAL TRANSLATION: IMPLICATIONS FOR PRACTICE
Surgical Practice
A longevity lens would redefine and optimize preoperative planning. Instead of viewing patient factors like poor skin quality or microvascular health as static risks, they become modifiable targets. Prehabilitation strategies could include growth factor–based topicals or nonablative lasers to improve epidermal barrier function and dermal collagen before surgery, potentially leading to improved outcomes, faster healing, and better scars. Postoperative, interventions could be tailored to support resolution of inflammation and promote optimal scar maturation.23
Nonsurgical Practice as Functional Preparation
Energy-based and injectable treatments could be sequenced not just for immediate cosmetic benefit but to “condition” tissue for future procedures or to maintain functional capacity. For example, regular biostimulatory injectable treatments, such as hyperdilute CaHA or PLLA, may maintain dermal support and tissue quality; according to perioperative expert consensus, patients treated with these agents generally remain suitable surgical candidates when appropriate timing and anatomical planes are respected, potentially deferring or optimizing the need for more invasive interventions.24-26
Retrospective clinical reports and randomized trials in scar management indicate that energy-based devices, including low-level lasers, pulsed dye lasers, and fractional modalities, improve scar outcomes by modulating collagen remodeling and enhancing tissue pliability and vascularity. These qualitative improvements in wound structure and healing are thought to correlate with more favorable surgical tissue handling and potentially reduced operative challenges compared with untreated fibrotic tissue.27-30 Retrospective observations suggest tissues treated with certain biostimulatory agents may handle surgery better but prospective trials are needed.
The Integrated Treatment Continuum
The most significant implication is the move toward a unified, lifelong aesthetic health plan. In this model, nonsurgical modalities maintain tissue biology and resilience during early aging, whereas surgical interventions are timed strategically based on biological need rather than chronological age alone. Postsurgical maintenance would then focus on preserving the result by supporting the biological health of the newly repositioned tissues.
Although several elements of this framework are already applicable in current clinical practice, particularly biostimulatory injectables, combination therapies, and strategies aimed at improving skin quality, this model primarily serves as a conceptual structure to guide a shift toward prevention, tissue quality, and long-term functional outcomes.
TRANSLATIONAL GAPS AND ETHICAL IMPERATIVES
Despite its promise, longevity aesthetics remains a largely conceptual and hypothesis-driven framework, and critical translational gaps must be addressed before widespread clinical implementation. First, there is no consensus on which cutaneous biomarkers, such as epigenetic clocks, SASP factors, or advanced glycation end-products, reliably reflect local vs systemic biological age or respond to aesthetic interventions. Second, aesthetic research remains dominated by short-term studies assessing outcomes over 6 to 12 months, resulting in a lack of longitudinal data on how repeated procedures influence tissue biology over years. Finally, the field lacks standardized, clinically feasible tools to objectively measure endpoints, such as “tissue resilience” or “regenerative capacity” in clinical practice.
Clinicians therefore have an obligation to clearly distinguish between established cosmetic outcomes and theoretical biological benefits, ensuring patient autonomy through transparent communication regarding the speculative nature of many pro-aging claims.
Importantly, this framework should be interpreted along a continuum between current practice and future innovation. Several elements are already actionable today, particularly the use of biostimulatory injectables, combination therapies, and strategies aimed at improving tissue quality and resilience rather than solely correcting volume loss. These approaches are increasingly integrated into routine clinical practice and align with the principles outlined in this model. In contrast, other components, such as validated cutaneous biomarkers, multi-omics-guided personalization (referring to the integrated analysis of genomics, transcriptomics, proteomics, metabolomics, and epigenomics), and predictive modeling through artificial intelligence, remain largely within the translational research domain.
At present, clinicians are not expected to directly implement these advanced tools or engage operationally with specialized fields such as biogerontology. Rather, the value of this framework lies in guiding a conceptual shift: encouraging clinicians to adopt a more preventive, tissue-quality-focused, and biologically informed approach while remaining strictly grounded in evidence-based practice. As research evolves, these emerging tools may progressively become accessible and clinically relevant, but their integration should follow robust validation and clear demonstration of clinical utility.
FUTURE DIRECTIONS
Future efforts must prioritize the development and validation of practical, clinically relevant cutaneous biomarkers that reliably reflect biological aging processes. This requires initiating prospective, longitudinal cohort studies that integrate multi-omics profiling with standardized aesthetic interventions to establish causal links and define durability. Furthermore, the field must establish clinically meaningful endpoints for “tissue health” and “resilience” that extend beyond subjective scales.
Ultimately, realizing the potential of longevity aesthetics depends on forging sustained interdisciplinary collaborations between aesthetic surgeons, dermatologists, and biogerontologists. By embracing this integrative approach with methodological rigor and ethical transparency, the aesthetic field can responsibly advance its practice and contribute meaningfully to the broader science of human health span.
CONCLUSIONS
Longevity aesthetics represents a conceptual evolution in aesthetic medicine, aligning clinical practice with the principles of geroscience by shifting the focus from the correction of visible aging to the preservation of tissue function and resilience. The skin provides a uniquely accessible model to explore whether aesthetic interventions can interact with biological aging processes. Although several elements of this framework are already reflected in current clinical practice, the overall model remains largely conceptual and hypothesis driven. Its future clinical relevance will depend on rigorous validation, long-term data, and continued integration of biological insights into evidence-based aesthetic care.
Acknowledgments
During the preparation of this work, the authors used FigureLabs AI (San Jose, CA) to create Figure 1. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of this figure.
Disclosures
The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.
Funding
The authors received no financial support for the research, authorship, and publication of this article, including payment of the article processing charge.